JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on September 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on several promising aspects of Intellia Therapeutics’ ongoing clinical trials. The company is set to present extended data from its ATTR-PN arm in the nex-z Phase 1 trial, showcasing up to three years of patient follow-up. This includes significant safety and serum TTR data, with previous updates indicating a substantial ~90% TTR knockdown sustained over 24 months. Such results suggest a strong potential for the treatment’s durability, which is crucial for its success in the competitive landscape of gene-editing therapies.
Moreover, the stability of mNIS+7 scores at the 12-month mark, comparable to existing RNAi/ASO TTR silencers, highlights the treatment’s effectiveness. While other approved therapies have shown stabilization up to 18 months, the potential for nex-z to maintain stable scores out to 24 months could position it favorably against current standards of care that require repeated administrations. Additionally, the safety profile of nex-z remains well-tolerated, with no major concerns from key opinion leaders, further supporting the Buy rating.
In another report released on September 19, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.